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Abstract
Background: Quality indicators are used to benchmark and 
subsequently improve quality of healthcare. However, defin-
ing good quality indicators and applying them to high-vol-
ume care such as skin cancer is not always feasible. Objec-
tives: To determine whether claims data could be used to 
benchmark high-volume skin cancer care and to assess clin-
ical practice variation. Methods: All skin cancer care-related 
claims in dermatology in 2016 were extracted from a nation-
wide claims database (Vektis) in the Netherlands. Results: 
For over 220,000 patients, a skin cancer diagnosis-related 
group was reimbursed in 124 healthcare centres. Conven-
tional excision reflected 75% of treatments for skin cancer 
but showed large variation between practices. Large prac-
tice variation was also found for 5-fluorouracil and imiqui-
mod creams. The practice variation of Mohs micrographic 
surgery and photodynamic therapy was low under the 75th 
percentile, but outliers at the 100th percentile were detect-
ed, which indicates that few centres performed these thera-
pies far more often than average. On average, patients re-
ceived 1.8 follow-up visits in 2016. Conclusions: Claims data 
demonstrated large practice variation in treatments and fol-
low-up visits of skin cancer and may be a valid and feasible 
data set to extract quality indicators. The next step is to in-
vestigate whether detected practice variation is unwarrant-
ed and if a reduction improves quality and efficiency of care.
© 2021 The Author(s)
Published by S. Karger AG, Basel
Introduction
The high incidence of skin cancer, the low mortality 
rate, the long lag time to recurrence and/or low rate of 
severe treatment-related complications make it difficult 
to monitor quality of skin cancer care [1]. Benchmarking 
is a monitoring method which originated within com-
mercial industry and has found its way into healthcare. 
Originally, benchmarking was used to improve organiza-
tional issues (e.g., staffing ratios) but soon after to im-
prove clinical outcomes by benchmarking clinical prac-
tice [2]. Benchmarking is a management approach which 
can be used to create a spirit of competition and to stimu-
late best practices at best cost [3]. A way to translate 
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benchmarking into medical care is often by using quality 
indicators. These quality indicators are thought to reflect 
quality of delivered care and can include items related to 
volume, complications and mortality rates [4]. 
Analyses of quality indicators can be used to reveal 
clinical practice variation, reflecting differences in care 
policy or outcomes between healthcare providers [5]. In 
only 15% of medical interventions, the choice of treat-
ment is clear and the differences in provider judgment are 
negligible (e.g., hospital admission rates for hip frac-
tures), making practice variation very common [6]. To a 
certain degree, practice variation is acceptable, but too 
much variation can be unwarranted and may be the result 
of under- or overtreatment [7, 8]. In the event of under-
treatment, patients may not receive the care they actually 
need, which reduces their chance of receiving optimal 
care. When overtreatment occurs, patients may be ex-
posed to unnecessary side effects and/or costs caused by 
intervening more than is medically justified [9]. For ex-
ample, an identical skin cancer patient may be treated by 
Mohs micrographic surgery (MMS) in one healthcare 
centre and by conventional excision in another centre.
There are sets of quality indicators which are manda-
tory to be registered for certain types of cancer in the 
Netherlands, such as complications and survival rates af-
ter resection of pancreas carcinoma and the number of 
incomplete resections of ovarian carcinoma [10]. How-
ever, for high-volume cancer such as skin cancer it is not 
feasible for healthcare providers to register quality indica-
tors for each patient [11]. Therefore, quality indicators for 
skin cancer are currently only registered for stage 3C or 
higher melanoma in specialised melanoma centres [10]. 
To obtain a complete overview of skin cancer care, rou-
tine data may be a promising data tool [12].
The aim of the current study is to determine whether 
claims data can be used to benchmark high-volume care 
and to assess whether there is clinical practice variation 
in type of treatment and number of follow-up visits of 
skin cancer patients. 
Patients and Methods
Data Source
Since 2005, all hospital visits and admissions in the Netherlands 
are categorised in diagnosis-related groups (DRGs). Each DRG in-
cludes all hospital activities and services associated with the patient 
care provided for a certain diagnosis. All activities related to diag-
nosis, treatment and follow-up are registered by the healthcare 
provider and included in a DRG, resulting in 1 reimbursement 
claim (Fig. 1) [13]. These claims are collected by healthcare insur-
ers and subsequently sent to a national information centre (Vektis 
B.V., Zeist) in the Netherlands. This nationwide claims database 
was used for the current study. As all Dutch inhabitants are obliged 
to have a healthcare insurance, the coverage is over 99% and a re-
cent study determined this database to be over 95% accurate when 
compared to local patient records [14]. 
Data Extraction and Analysis
All patients with a DRG reimbursed for a cutaneous malignan-
cy within dermatology care in the most recent available calendar 
year (2016) were included. This includes patients who were diag-
nosed before 2016 but only had a follow-up visit in 2016. The data 
sets only included cutaneous malignancies (i.e., basal cell carci-
noma, squamous cell carcinoma, melanoma and rare types of skin 









Fig. 1. Example of a diagnosis-related group (DRG) for a skin can-
cer patient. In this schematic example, a patient received a biopsy 
during the first visit, during the second visit the skin cancer was 
removed by conventional excision, then the sutures were re-
moved, and thereafter, the patient received 2 follow-up visits. The 
conventional excision was included in the analyses of practice 
variation of treatments. The last 2 outpatient clinic visits, without 
any other registered activity on the same day, were considered 
follow-up visits and included in practice variation analysis of fol-
low-up visits.




keratosis, were not included. It is not possible for patients to have 
diagnosis codes for both a cutaneous malignancy and a pre-malig-
nancy (e.g., squamous cell carcinoma and actinic keratosis). Un-
fortunately, there were no specific diagnosis codes for each subtype 
of skin cancer. The ICD-10 codes were introduced from 2016, 
which differentiates between different subtypes of skin cancer (ex-
cept for basal cell carcinoma and squamous cell carcinoma), but 
the saturation of this data was too poor to use for the current study. 
Two data sets were extracted from Vektis’ nationwide claims da-
tabase, based on healthcare activities (Fig. 1).
One data set contained types of treatment indicated for skin 
cancer: conventional excision, MMS, photodynamic therapy 
(PDT), 5-fluorouracil and imiquimod cream. Destructive thera-
pies, such as cryotherapy, were not included, because patients 
could be treated this way for their actinic keratosis during follow-
up for their skin malignancy. If a patient received multiple treat-
ments, e.g., topical treatment and excision, both treatments were 
registered. The number of treatments were stratified per health-
care centre. 
The second data set contained the number of follow-up visits 
and was also stratified per healthcare centre. A follow-up visit was 
defined as a visit at the dermatology outpatient clinic after a skin 
cancer treatment, without any other activity registered on that day 
(e.g., removing sutures). 
The maximum timeframe of an initial DRG is 90 days, and 120 
days for a subsequent DRG. When this time limit has passed and 
a new care activity is registered for this patient for the same diag-
nosis, a subsequent DRG will be opened. The eligible DRG codes 
are listed in online supplementary Table S1 (for all online suppl. 
material, see www.karger.com/doi/10.1159/000513523). The 
number of referrals from other healthcare centres was determined 
by searching for a skin cancer DRG at another healthcare centre 
up to 90 days prior to the DRG in the main analysis (i.e., tertiary 
care). The healthcare centres were categorised as university hospi-
tal, general hospital or independent sector treatment centre and 
anonymised for the researchers. 
The analyses were performed by using SAS software (version 
9.3; SAS Institute Inc., Cary, NC, USA) and Microsoft Excel (Mi-
crosoft, Redmont, WA, USA). Charts were created of the distribu-
tion of treatment types and average number of follow-up visits per 
centre. Finally, after the healthcare centres were ranked according 
to the proportion of type of treatment or follow-up visits, percen-
tiles (p0, p25, p50, p75, p100) and the differences between percen-
tiles (p25–p75 and p0–p100) were determined to reveal practice 
variation. To determine whether results are skewed by small 
healthcare centres, a sensitivity analysis was performed by exclud-
ing the centres with the lowest quartile in terms of number of pa-
tients.
Results
In total, 124 healthcare centres in the Netherlands re-
imbursed at least 1 DRG for a skin malignancy within 
dermatology care in 2016 for over 220,000 unique pa-
tients (Table 1). The total number of patients is higher 
than the total number of treatments, as patients who sole-
ly received follow-up care in 2016 were included as well. 
Nearly 400,000 follow-up visits took place in dermatology 
care for skin cancer in 1 year.
Treatments
An overview of the type of treatment quality indicator 
scores per healthcare centre is displayed in Figure 2. In 
2016, general hospitals were the most consistent in treat-
ing their skin cancer patients by conventional excision, of 
which the hospitals with the least conventional excisions 
were performing more MMS. The 2 independent sector 
treatment centres with the highest percentage of MMS 
(30 and 24%) had a substantial proportion of their pa-
tients referred from other healthcare centres (24 and 
17%). The university hospital with 33% MMS had 35% of 
their patients referred from other healthcare centres, 
compared to 2–13% referred patients of the other univer-
sity hospitals. 
Patients in university hospitals were treated with 5-flu-
orouracil or imiquimod cream in 22% of the cases, com-
pared to 15 and 12% of patients in general hospitals and 
Table 1. Total number and distribution of treatments and follow-up visits for a skin malignancy per type of treat-
ment centre in 2016










ISTCs, n (%) 46 (37.1) 24,857 (11.2) 55,462 (14.1) 17,125 (12.6)
General hospitals, n (%) 74 (59.7) 180,525 (81.4) 304,980 (77.4) 108,758 (80.2)
University hospitals, n (%) 8 (6.5) 16,498 (7.4) 33,530 (8.5) 9,715 (7.2)
Total 124 221,880 393,972 135,598
ISTCs, independent sector treatment centres. a Healthcare centres with at least 1 patient with a follow-up visit 
for a skin malignancy. b Patients with at least 1 follow-up visit for a skin malignancy in 2016. c Conventional 
excision, Mohs micrographic surgery, photodynamic therapy, 5-fluorouracil and imiquimod cream. 
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independent sector treatment centres, respectively (on-
line suppl. Fig. S1). In independent sector treatment cen-
tres, 6% of skin cancer patients were treated with PDT, 
while in university and general hospitals 1 and 3% of pa-
tients were treated with PDT, respectively.
On average (taking the 50th percentile), 77.0% of all 
malignancies were treated by conventional excision in 
2016 (Table 2). This proportion was reasonably compa-
rable with the application of conventional excision in 
the 25th (71.3%) and 75th percentile (82.4%). The outli-
ers, however, also showed healthcare centres with only 
33.3% (p0) or more than 90% (p100) use of convention-
al excision. Most practice variation is revealed for topi-
cal treatment for skin cancer (5-fluorouracil and imiqui-
mod), as the p0–p100 ranges from 0 to 66.7%. The low 
percentages of MMS and PDT until the 75th percentile 
(< 7%) and the high percentage at p100 (> 32%) indicate 
that few healthcare centres provided that care more of-
ten in 2016. 
Follow-up Visits
Figure 3 provides an overview of the number of follow-
up visits per healthcare centre. The average number of 













University General hospitals ISTCs
■ Conventional excision ■ Mohs micrographic surgery ■ 5-Fluorouracil or imiquimod ■ Photodynamic therapy
Table 2. Percentiles of the distribution of quality indicator scores of different types of skin malignancy treatments 
and follow-up visits between healthcare centres in 2016
p0 p25 p50 p75 p100 Difference between
p25–p75 p0–p100
Conventional excision, % 33.3 71.3 77.0 82.4 90.6 11.1 57.2
Mohs micrographic surgery, % 0 0.9 3.0 6.7 32.8 5.8 32.8
5-Fluorouracil or imiquimod, % 0 10.5 14.6 18.5 66.7 7.9 66.7
Photodynamic therapy, % 0 0.6 1.8 6.1 39.5 5.5 39.5
Average number of follow-up visits per patient 0.44 1.48 1.75 2.01 6.61 0.53 6.17
Fig. 2. Distribution of quality indicator scores of the treatments indicated for skin cancer in 2016. Each bar rep-
resents 1 healthcare centre. University, University hospitals; ISTCs, independent sector treatment centres.




tals, 1.7 for general hospitals and 2.0 for independent sec-
tor treatment centres. The 14 healthcare centres with the 
highest number of follow-up visits per patient were all 
independent sector treatment centres with an average of 
2.4–6.6 follow-up visits per patient.
The difference in the average number of follow-up vis-
its between healthcare centres, the 25th percentile and the 
75th percentile, was 0.53 follow-up visits per patient (Ta-
ble 2). The number of follow-up visits per patient at these 
percentiles (1.48–2.01) did not differ much from the 50th 
percentile (1.75). However, the p100, showing an average 
number of follow-up visits of 6.61 per patient, reveals that 
there were some healthcare centres on the higher end 
contributing to practice variation. 
The sensitivity analysis, which was used to detect 
whether results were skewed by small healthcare centres, 
did not differ from the main analysis concerning the in-
terquartile range (p25–p75). The results of the sensitivity 
analysis were different from the main analysis on the p0–
p100 range of topical treatments (25.2%) and follow-up 
visits (2.1). This means that healthcare centres with a rel-
atively small number of skin cancer patients deviate more 
from the 50th percentile and caused more practice varia-
tion than larger healthcare centres regarding these qual-
ity indicators.
Discussion
This study shows that claims data is able to detect rel-
evant clinical practice variation in terms of skin cancer 
treatment and follow-up care. Proportion of specific 
treatments and follow-up could be valid quality indica-
tors and routinely collected claims data may be a good 
data source for benchmarking. 
The amount of clinical practice variation was highest 
for conventional excision, followed by topical creams. 
This variation could be explained by the referral rate of 
dermatologists to plastic surgeons depending on his/her 
surgical experience and skills, or the available facilities of 
the healthcare centre to provide high numbers of exci-
sions. The practice variation in MMS and PDT was low 
under the 75th percentile, but outliers at the 100th per-
centile were detected. MMS and PDT are treatments 
which were (and are) not provided in all healthcare cen-
tres, which means that there has to be practice variation. 
As shown by Arits et al. [15], PDT is both more expensive 
and less effective than 5-fluorouracil and imiquimod 
cream, which led to guideline changes in 2014 [16]. The 
high amount of PDT in some healthcare centres might be 
explained by lack of knowledge of the guideline change. 
The near 100% compliance rate of conventional PDT 
might be a rationale to prefer this treatment for a subset 



































■ ISTCs ■ General hospitals ■ University hospitals
*
Fig. 3. Average number of follow-up visits per patient per healthcare centre in 2016. Each bar represents 1 health-
care centre. ISTCs, independent sector treatment centres. * The y-axis was cut off at 4.0 for clarity; this healthcare 
centre’s value was 6.6.
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comply with creams at home (e.g., stopping treatment too 
early due to side effects). However, it may also have been 
stimulated by a financial incentive, as PDT is more profit-
able for healthcare centres than conventional excision 
and topical treatments.
The average amount of follow-up visits per skin cancer 
patient was 1.8 in 2016. Considering that skin cancer pa-
tients comprise 24% of all dermatology patients, these fol-
low-up visits account for a large part of dermatology care 
[17]. Comparing the 25th percentile to the 75th percentile 
indicates little practice variation between healthcare cen-
tres regarding the number of follow-up visits per skin 
cancer patient. However, it is remarkable that the 14 
healthcare centres with the highest number of follow-up 
visits per patient were all independent sector treatment 
centres.
Making use of claims data has some limitations. As the 
information was aggregated, it should be interpreted 
carefully. It does not allow analyses on absolute frequen-
cies, but rather a comparison of relative frequencies be-
tween healthcare providers. No conclusions regarding 
under- or overtreatment can be drawn on the basis of 
practice variation found in the current study, because 
centres could treat different patient populations. For in-
stance, due to lack of detailed information on the patient 
level (e.g., age, type of tumour), the case mix of each cen-
tre could not be determined. For this reason, it was not 
possible for the authors to determine whether the high 
percentage of MMS and high number of follow-up visits 
are due to specialisation in complex skin cancer care. Al-
though the number of referrals provides an indication, no 
causality can be established. Strengths of claims databas-
es are that it is routinely registered data, it is virtually 
complete due to obligatory registration and that the sum-
maries of quality indicators of claims data match summa-
ries of quality indicators of the actual medical records 
[18].
The next step is to determine whether the practice 
variation found in our study is warranted. Institutions 
such as the Ministry of Health or health insurers (in col-
laboration with clinical experts) could request healthcare 
centres to retrieve their own quality indicator scores from 
Vektis and investigate why certain centres deviate from 
the average. This process of audit and feedback might al-
ready effectively reduce possible unwarranted practice 
variation [19]. There are several other options to reduce 
the variation, such as the development and implementa-
tion of guidelines (most common strategy), improving 
shared decision-making and introduction of financial in-
centives [20–25]. Multifaceted strategies have been prov-
en to be more effective in reducing practice variation than 
single strategies [26].
In conclusion, claims data can be used to benchmark 
high-volume care and to reveal clinical practice variation 
on routinely collected quality indicators. The current 
study revealed that there might be under- and/or over-
treatment in the case of conventional excisions and topi-
cal creams. In addition, it showed that there is little prac-
tice variation regarding follow-up visits, but it was sur-
prising to see that the 14 healthcare centres with the 
highest number of follow-up visits per patient were all 
independent sector treatment centres. It should be ex-
plored if the variation found in the current study is war-
ranted and if further actions should be undertaken to re-
duce the practice variation. 
Key Message
Analysis of claims data revealed large practice variation in skin 
cancer treatments and follow-up care
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